PGE2 Induces IL-6 in Orbital Fibroblasts through EP2 Receptors and Increased Gene Promoter Activity: Implications to Thyroid-Associated Ophthalmopathy by Raychaudhuri, Nupur et al.
PGE2 Induces IL-6 in Orbital Fibroblasts through EP2
Receptors and Increased Gene Promoter Activity:
Implications to Thyroid-Associated Ophthalmopathy
Nupur Raychaudhuri
1, Raymond S. Douglas
1, Terry J Smith
2*
1Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, United States of America, 2Department of
Ophthalmology and Visual Sciences and Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, United States of America
Abstract
Background: IL-6 plays an important role in the pathogenesis of Graves’ disease and its orbital component, thyroid-
associated ophthalmopathy (TAO). Orbital tissues become inflamed in TAO, a process in which prostanoids have been
implicated. Orbital fibroblasts both generate and respond to PGE2, underlying the inflammatory phenotype of these cells.
Methodology/Principal Findings: Using cultured orbital and dermal fibroblasts, we characterized the effects of PGE2 on IL-6
expression. We found that the prostanoid provokes substantially greater cytokine synthesis in orbital fibroblasts, effects that
are mediated through cell-surface EP2 receptors and increased steady-state IL-6 mRNA levels. The pre-translational up-
regulation of IL-6 results from increased gene promoter activity and can be reproduced with the PKA agonist, Sp-cAMP and
blocked by interrupting the PKA pathway. PGE2-induced production of cAMP in orbital fibroblasts was far greater than that
in dermal fibroblasts, resulting from higher levels of adenylate cyclase. PGE2 provokes CREB phosphorylation, increases the
pCREB/CREB ratio, and initiates nuclear localization of the pCREB/CREB binding protein/p300 complex (CBP) preferentially in
orbital fibroblasts. Transfection with siRNAs targeting either CREB or CBP blunts the induction of IL-6 gene expression. PGE2
promotes the binding of pCREB to its target DNA sequence which is substantially greater in orbital fibroblasts.
Conclusion/Significance: These results identify the mechanism underlying the exaggerated induction of IL-6 in orbital
fibroblasts and tie together two proinflammatory pathways involved in the pathogenesis of TAO. Moreover, they might
therefore define an attractive therapeutic target for the treatment of TAO.
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Introduction
In the autoimmune thyroid syndrome, Graves’ disease, the orbit
becomes inflamed and undergoes extensive tissue remodeling, a
condition known as thyroid-associated ophthalmopathy
2 (TAO)
[1,2]. A cardinal feature associated with TAO is the substantial
infiltration of both B and T lymphocytes within orbital connective
tissues [3–5]. Several cytokines, including IL-6, have been
implicated in the pathogenesis of autoimmune diseases [6].
Hiromatsu et al. [7] studied the cytokine profiles of patients with
Graves’ disease and TAO. They found that extra-ocular eye
muscle and orbital fat from these individuals express high levels of
IL-6 mRNA and that orbital volumes correlated positively with
levels of these transcripts. These findings may prove particularly
relevant to antibody-driven autoimmune diseases like Graves’
disease since IL-6 supports B lymphocyte and plasma cell function
and is a recognized cofactor in fat metabolism [8,9].
Orbital fibroblasts exhibit a unique set of phenotypic attributes
when activated by cytokines and bioactive lipids. They can
generate powerful chemoattractants and proinflammatory signals.
These are currently believed to underlie the susceptibility of the
orbit to inflammation such as that occurring in TAO [10]. Orbital
fibroblasts produce extraordinarily high levels of prostaglandin E2
(PGE2) when treated with cytokines [11–13]. At the heart of this
response is an exaggerated induction of prostaglandin endoper-
oxide H synthase-2 (PGHS-2), the rate limiting, inflammatory
cyclooxygenase involved in the production of PGE2 [14]. PGHS-2
has been found over-expressed in orbital tissues from patients with
TAO [15]. Moreover, both B and T cells have substantial capacity
to generate PGE2 through the induction of PGHS-2 which occurs
in their activated states [16–18]. Thus, the capacity of orbital
tissue in TAO to generate PGE2 may be increased dramatically.
PGE2 acts on target cells through one or more EP receptors, some
of which are coupled to G protein through which adenylate
cyclase activation leads to increased intracellular cAMP [19].
A number of factors have been shown to regulate the expression
of IL-6 in a variety of cell-types [20–22]. Transcriptional
regulation of the IL-6 gene is complex and involves the cAMP
response element (CRE)-binding protein (CREB). Phosphorylated
CREB is recruited to the nucleus and complexes with CREB
binding protein/p300 (CBP) [20]. The amplitude of CREB
mediated transcriptional effects is determined at least in part on
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3the nature of an interaction between CREB and CBP [23].
Specifically, the two proteins interact following phosphorylation of
the Ser-133 residue on CREB. This phosphorylated protein then
identifies the 94 amino acid Kix domain on CBP [24]. Thus,
transcriptional up-regulation of target genes resulting from cAMP
generation relies on the formation of a CREB/CBP complex.
In an earlier paper, we demonstrated that IL-1b could induce
the production of IL-6 in orbital fibroblasts in an anatomically
selective manner [25]. That effect was mediated through an up-
regulation of IL-6 gene promoter activity and was transient, lasting
for only a few hours. Since that report, several other groups have
detected dramatic over-expression of PGHS-2 in orbital tissues
affected with TAO, especially in the early active phase [15,26],
suggesting a state where PGE2 and potentially other prostanoids
might be generated in vivo. We have described the expression and
highly inducible PGHS-2 and its enzymatic partner, microsomal
PGE2 synthase, in IL-1b, leukoregulin, and CD154-activated
TAO orbital fibroblasts [11–13]. Here, we explore the potential
relationship between PGE2 and IL-6 production in TAO-derived
orbital fibroblasts. The induction by PGE2 of IL-6 is mediated
through cell-surface EP2 receptors, an intermediate generation of
intracellular cAMP, and the obligatory formation of a nuclear
complex comprising CREB and CBP/p300. Knocking down
either CREB or CBP expression dampens the level of IL-6
induction. Our findings for the first time demonstrate the potential
importance of exaggerated PGE2 generated in orbital fibroblasts
as an autocrine regulatory factor.
Results
PGE2 induced IL-6 expression in orbital fibroblasts in an
anatomic site-selective, time- and dose-dependent
manner
IL-6 production in untreated orbital fibroblasts occurred at a
very low level but when PGE2 was added to the culture medium,
levels of the cytokine were increased substantially. As the data in
Fig. 1A demonstrates, even at the lowest concentration of the
prostanoid tested (1 nM), an effect was detectable and reached
statistical significance. The response was near maximal at 0.1 mM,
where it was 4.5-fold above baseline. Increasing the concentration
by 100-fold failed to increase synthesis further. The effects were
rapid and at 6 hr, IL-6 concentrations in the medium had
increased by nearly five-fold (Fig. 1B). They continued to increase
for 16 hr when they were 5.9-fold above untreated levels
(p,0.0001) and they remained elevated for 24 hr, the duration
of the study. The induction was 82% greater in three orbital
fibroblast strains compared to that in three from the skin (Fig. 1C,
p,0.01). The level of cell layer-associated IL-6 achieved in orbital
fibroblasts following PGE2 treatment for 16 hr. was dramatically
greater than that in dermal fibroblasts (.5-fold vs ,10%, Fig. 1D).
Figure 1. IL-6 production in orbital fibroblasts is induced by
PGE2 in a concentration- and time-dependent manner. Conflu-
ent orbital cultures, in this case from a patient with TAO, were treated
A: with escalating concentrations of PGE2 for 16 h. or B: with PGE2
(1 mM) for graded intervals or . C: with or without PGE2 (1 mM) for 16 h
in three different dermal and orbital fibroblast strains, each from a
different donor. Media were collected and subjected to ELISA analysis
as described in Materials and Methods. Data are expressed as the mean
6 SD of triplicate determinations. * denotes P,0.005 compared to PGE2
treatment alone. D: Orbital and dermal cultures were treated with
nothing or with PGE2 (1 mM) for 16 h., and cell layer protein was
collected and analyzed by Western blot for IL-6 protein. Membranes
were then re-probed with anti-b actin antibody as a loading control.
Band densities, corrected for their respective b-actin signals: Dermal
control, 0.132, Dermal PGE2, 0.146; Orbital control, 1.098; Orbital PGE2,
5.132.
doi:10.1371/journal.pone.0015296.g001
PGE2 Regulates IL-6 Expression
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involved the induction of its mRNA and gene promoter
activity
The time interval between initiation of the treatment with PGE2
and a detectable increase in IL-6 protein suggested action at the
pre-translational level. This was born out since IL-6 steady-state
mRNA was increased by PGE2 (1 mM). As the real-time RT-PCR
analysis in Fig. 2A indicates, TAO orbital fibroblasts expressed
higher basal levels of IL-6 mRNA than did those from the skin.
Levels in untreated orbital fibroblasts were 3.4-fold above those in
dermal cultures (p,0.001 vs. dermal) and increased after 16 hr of
treatment with PGE2. The magnitude of the increase was 1.75-fold
in the orbital fibroblasts (p,0.01 vs. basal). In contrast, PGE2
failed to increase IL-6 mRNA levels significantly in the dermal
cultures.
To determine whether PGE2 was acting to enhanced IL-6 gene
transcription, a fragment of the IL-6 gene promoter was cloned
and fused to a luciferase reporter gene, and transiently transfected
into orbital and dermal fibroblasts. .After 1 hr, the reporter gene
activity was significantly higher in PGE2-treated TAO orbital
fibroblasts than that found in identically treated dermal fibroblasts
(Fig. 2B). The prostanoid increased promoter activity by 2.8-fold
in orbital fibroblasts while increasing the activity by only 80% in
dermal cells (p,0.0001 and p,0.005, respectively).
PGE2-induced IL-6 production was mediated through
cAMP generation and PKA
PGE2 can exert its actions through one of several signaling
pathways, depending on the receptor subtype through which the
cellular response was mediated. With regard to the induction of
IL-6 by the prostanoid, the JAK2 inhibitor, AG490 (10 mM), PI3
kinase inhibitor, LY294002 (10 mM), JNK inhibitor, II 420119
(10 mM), and protein kinase C inhibitor, Calphostin C (100 nM)
all failed to inhibit the PGE2-induced IL-6 production (data not
shown). In contrast, H89 (10 mM), a specific PKA inhibitor,
dramatically reduced the effects of PGE2 on IL-6 while Sp-cAMP
(1 mM), a cAMP analog, mimicked PGE2-induced IL-6 synthesis
(Fig. 3).
PGE2-mediated IL-6 synthesis involved phosphorylation
of CREB in fibroblasts
PGE2 treatment resulted in rapid CREB phosphorylation in
orbital fibroblasts, peaking at 5–15 min (Fig. 4A). The pCREB/
CREB ratio remained constant in dermal fibroblasts but increased
significantly in those from the orbit after 15 min of treatment. H89
abolished PGE2-induced CREB phosphorylation, suggesting that
it was mediated through an increased intracellular cAMP
Figure 2. PGE2 upregulates IL-6 mRNA and IL-6 gene promoter
activity. A: Divergent levels of IL-6 protein induced by PGE2 in orbital
and dermal fibroblasts are reflected in the abundance of IL-6 mRNA.
Fibroblasts were treated with nothing or PGE2 (1 mM) for 16 h. Ct values
were normalized to GAPDH and expressed as fold-change. Data are
expressed as the mean 6 SD of triplicate independent determinations
from one dermal and one orbital fibroblast cell. In 3 different strains of
each, basal IL-6 mRNA levels were 3.2 fold greater in orbital fibroblasts.
Following PGE2 (1 mM) for 16 h, levels were 3.7-fold higher in orbital
versus dermal fibroblasts. B: PGE2 upregulated IL-6 gene promoter
activity in orbital and dermal fibroblasts transiently transfected with
empty luciferase vector or that construct fused to an 1171-nt fragment
spanning 21168 to +3 nt of the human IL-6 gene promoter. Cultures
were then treated with nothing (control) or PGE2 (1 mM) for 1 h. Data
are expressed as the mean 6 SD of triplicate independent determina-
tions. * denotes statistical difference between groups. In another study,
3 different orbital fibroblast strains demonstrated 2.6 fold greater IL-6
promoter activity compared to dermal fibroblasts following 1 h
treatment with PGE2 (1 mM).
doi:10.1371/journal.pone.0015296.g002
Figure 3. PGE2-induced IL-6 production can be attenuated by
inhibitors of PKA. Confluent orbital fibroblasts, in this case from a
patient with TAO, were treated with PGE2 (1 mM) or Sp-cAMP (1 mM) in
the absence or presence of H89 (10 mM). Media were collected and
analyzed for IL-6 content after 16 hr incubations. Data are presented as
the mean 6 SD of triplicate independent determinations from a single
orbital fibroblast strain. . This result was confirmed in two other orbital
fibroblast strains where IL-6 production was reduced 5.6 fold by H89.
* denotes P,0.005 compared to PGE2 treatment alone; ** denotes
P,0.005 compared to no treatment.
doi:10.1371/journal.pone.0015296.g003
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measured and basal levels were comparable in untreated orbital
and dermal fibroblasts (Fig. 5A). PGE2 (1 mM) increased cAMP
generation by 12.6-fold in orbital while only 2.3-fold in dermal
cells (Fig. 5A). This suggested that the orbital fibroblasts had a
substantially greater capacity for generating cAMP. Generation of
the cyclic nucleotide was then compared in three orbital and three
dermal strains. cAMP levels were consistently higher in the orbital
fibroblasts, especially following treatment with PGE2 (Fig. 5B).
Levels of adenylate cyclase were then determined by Western blot
analysis. The analysis disclosed substantially higher levels of
enzyme expression in orbital fibroblasts (orbital 65610 vs dermal
3169 AU, p,0.005) (Fig. 5C). Thus, divergent levels of adenylate
cyclase might represent the basis for the greater cAMP generation
in response to PGE2.
EP2 receptor mediated the action of PGE2 in TAO orbital
fibroblasts
Several receptors displayed on the cell surface can mediate
the actions of PGE2 [29]. Moreover, the EP2 subtype receptor
displayed on orbital fibroblasts mediates other actions of
endogenous and exogenous PGE2 [30,31]. We next set out to
determine whether the higher level of cAMP generation and IL-
6 production in orbital fibroblasts was, at least in part, a
consequence of greater EP receptor display. The EP2–selective
agonist, Butaprost, could induce IL-6 synthesis as did authentic
PGE2 ( F i g .6 A ) .D e r m a lf i b r o b l a s ts failed to respond (not
shown). Moreover, the EP2 antagonist, AH6809 (10 mM),
reduced appreciably the PGE2-induced IL-6 production in
orbital fibroblasts. The EP4 antagonist GW627368X (10 mM)
failed to influence PGE2-stimulated IL-6 production, strongly
suggesting that EP4 is not involved in these actions of PGE2.W e
next assessed levels of the EP2 receptor by flow cytometry. As
the flow plots shown in Fig. 6B demonstrate, the abundance of
EP2 appeared equivalent on dermal and orbital fibroblasts
despite differences in the magnitude of IL-6 induction and
cAMP generation provoked by PGE2. Both the fraction of EP2
+
cells and the receptor densities were similar in the two
populations of fibroblasts. Thus, the divergent magnitude of
IL-6 induction could not be attributed to differences in EP2
receptor levels.
Figure 4. PGE2 provokes the phosphorylation of CREB in orbital fibroblasts, an effect blocked with H89. A: Confluent cultures were
treated with PGE2 (1 mM) for different intervals. Cellular proteins were subjected to Western blot analysis of CREB and pCREB. Densitometric analysis
of pCREB protein concentrations are expressed as the ratio to total CREB protein as a percent of the value at ‘‘0’’ min. Data are expressed as the mean
6 SD of triplicate independent determinations. (* denotes statistical significance between treatment groups). B: H89 (10 mM) inhibits PGE2-provoked
CREB phosphorylation in orbital fibroblasts. The inhibitor was added for 6 hrs, followed by addition of PGE2 (1 mM) for 15 min. Cellular proteins were
subjected to Western blot analysis of pCREB protein using b-actin as a loading control.
doi:10.1371/journal.pone.0015296.g004
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complexes in orbital fibroblasts
Given the strong suggestion from the preceding findings, it
appeared that CREB phosphorylation might play an important
role in mediating the induction by PGE2 of IL-6.
The impact of knocking down CREB with a specific siRNA on
IL-6 induction in orbital fibroblasts was then determined. As
Fig. 7A demonstrates, treating orbital fibroblasts with CREB
siRNA could efficiently interrupt CREB protein expression, under
basal and PGE2-treated conditions. The importance of CREB to
the induction of IL-6 by PGE2 was then demonstrated by the
attenuation of cytokine production following transfection with
CREB siRNA (Fig. 7B). Optimal transcriptional activation of
certain gene promoters containing CRE requires an association
between pCREB and CBP [32]. We attempted to determine
whether PGE2 influenced CREB binding to CBP. The immuno-
precipitation of CBP could bring pCREB out of solution in lysates
derived from orbital fibroblasts following treatment with PGE2 for
15–20 min. (Fig. 8A). Alternatively, subjecting these lysates to
antibodies directed against pCREB resulted in immunoprecipita-
tion of CBP complexed with pCREB from these same nuclear
extracts (Fig. 8B). As the study clearly demonstrated, there was no
detectable complex precipitation in nuclear lysates from similarly
treated dermal fibroblasts. This result indicates that the basis for
divergent IL-6 induction by PGE2 in orbital fibroblasts concerns,
at least in part, the cell-type specific interaction between pCREB
and CBP following treatment with the prostanoid. Fig. 8C
demonstrates that CBP siRNA reduced the yield of pCREB co-
immunoprecipitated with anti-CBP. Analogous to the findings
Figure 5. PGE2 induces more robust cAMP generation in orbital
compared to dermal fibroblasts resulting from higher levels of
adenylate cyclase. A: Confluent cultures were serum starved for 20 h
and then treated with PGE2 (1 mM) for 16 hrs. Cells were then lysed with
0.1 N HCl and cAMP was measured by cAMP immunoassay. Data are
presented as the mean 6 SD of three independent determinations.
(* indicates statistical differences between groups). B: cAMP levels in
three different dermal and orbital fibroblast strains treated with nothing
or PGE2 (1 mM) for 16 hrs. Data are presented as the mean 6 SD of
three independent determinations. The level of cAMP produced in
orbital fibroblasts is 3 fold (p,0.05) greater than in dermal fibroblasts,
C: Orbital fibroblasts express higher adenylate cyclase levels when
compared to dermal fibroblasts. Data derived from Western blot
analysis of three separate dermal and orbital fibroblast strains. These
were normalized to their respective b-actin levels. They are expressed as
the mean 6 SD, p,0.005, n=3.
doi:10.1371/journal.pone.0015296.g005
Figure 6. EP2 mediates the actions of PGE2 on IL-6 expression
in orbital fibroblasts. A: Confluent cultures were treated with
nothing, Butaprost (10 mM) or PGE2 (1 mM) in presence or absence of
EP2 inhibitor AH6809 (10 mM), EP4 inhibitor GW627368X (10 mM) for
16 h. Media were subjected to IL-6 ELISA. Data are expressed as mean
6 SD of three independent determinations. * denotes P,0.005
compared to PGE2 alone, ** denotes P,0.005 compared to no
treatment. B: Comparison of surface EP2 receptor display by orbital
and dermal fibroblasts as determined by flow cytometry. L6 cells serve
as the positive control. Inset histograms represent the levels of shift
when compared with isotype.
doi:10.1371/journal.pone.0015296.g006
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could also significantly attenuate the induction of IL-6 (Fig. 8D).
Thus both components of the CREB/CBP/p300 complex are
necessary for an optimal induction by PGE2 of IL-6. PGE2
treatment results in a substantial enhancement of pCREB binding
to target DNA (Fig. 9). The effects on DNA binding are
substantially greater in orbital fibroblasts than those found in
dermal cultures.
Discussion
IL-6 exerts diverse influence on adipose tissues such as those
present in the human orbit. Moreover, the cytokine has been
implicated in the pathogenesis of obesity where it may determine
the pattern of fat accumulation throughout the body [33–35]. A
limited number of studies have examined PGE2 effects on IL-6
expression in other cell types. For instance, PGE2 upregulates
cAMP levels in the rat intestinal epithelial cell line, IEC-6, and in
so doing enhances endotoxin-induced IL-6 production [36]. In the
human early leukemia T cell line, HSB.2, misoprostol, an EP4/
EP2/EP3 selective agonist, induces IL-6 mRNA and increases IL-6
secretion, effects related to the activities of PKA but not PKC [37].
In tissue-infiltrating macrophages, the upregulation by PGE2 of
IL-6 is mediated through EP4 receptors and PKC signaling [38].
None of these earlier studies examined the mechanisms involved in
the transcriptional regulation of the IL-6 gene by the prostanoid.
The results presented here tie together two potentially
important aspects of the divergent phenotype displayed by orbital
fibroblasts. The cellular attributes peculiar to orbital fibroblasts
may underlie, at least in part, their roles in the pathogenesis of
TAO. In particular, they produce substantial levels of PGE2 when
activated and can also respond to the prostanoid in a cell-specific
manner [30,31]. These responses to PGE2 are unusually robust
and can result in dramatic morphological changes that are driven
by cAMP generation. The current study sheds new insight into the
mechanism underlying the high capacity for the generation of
cAMP in orbital fibroblasts because we report the substantially
higher levels of adenylate cyclase they express (Fig. 5B). It may
have direct relevance to thyrotropin receptor function, especially
in the context of Graves’ disease. That receptor utilizes a G
protein-coupled mechanism for cAMP generation as a principal
signaling pathway in the thyroid [39]. IL-1b, leukoregulin, and
CD154 promote PGE2 generation in these fibroblasts through a
mechanism that involves the de novo synthesis of PGHS-2, the rate
limiting synthetic enzyme in the production of PGE2 [12–14]. IL-
1b and CD154 also induce IL-6 in orbital fibroblasts, unlike
several other primary human fibroblasts [25,40]. PGE2 exerts its
own positive effects by up-regulating IL-6 gene transcription.
Thus, our current findings suggest that PGE2 functions as a
positive regulator of IL-6 production in orbital connective tissues,
accounting for at least in part the high levels thought to be
achieved in TAO [7].
The actions of PGE2 on IL-6 are mediated through the
activation of EP2 receptors, generation of cAMP, and the
recruitment of CREB/CBP/p300 complex to the orbital fibroblast
nucleus. While levels of EP2 receptor appear similar in dermal and
orbital fibroblasts, those of cAMP generated as a consequence of
PGE2 exposure are dramatically different in the two cell types
(Fig. 5A, 5B). Moreover, the magnitude of IL-6 induction was
similarly divergent suggesting that the levels of cAMP generated
may determine, at least in part, the magnitude of cytokine
production. This appears to result from the higher levels of
adenylate cyclase in orbital fibroblasts. CBP/p300 was initially
implicated the transcriptional activation imposed by phosphory-
lated CREB [41]. It functions in a dual role within the nucleus,
serving as both a histone acetyltransferase and as a transcriptional
adaptor molecule [42]. The phosphorylation of CREB at Ser 133
can be mediated through the Akt pathway, results in the
recruitment of CBP, and may help explain the role of CREB/
CBP/p300 in enhanced cell survival [43]. CBP/p300 recruitment
is mediated through changes in nuclear calcium and calcium/
clamodulin-dependent protein kinase IV activity, but complex
recruitment apparently does not necessarily result in CREB/CBP/
p300-dependent transcriptional activation [44]. It would appear
that the actions of PGE2 described here are mediated through the
formation of the CREB/CBP/p300 complex (Figs. 7 and 8).
Interruption of either component with the respective siRNAs
results in an attenuation of IL-6 expression. pCREB/CREB levels
increase selectively in orbital but not in dermal fibroblasts
following exposure to PGE2 (Fig. 4A). This phosphorylation can
be blocked with a PKA inhibitor (Fig. 4B). The point of divergence
between responses in dermal and orbital fibroblasts appears to
reside upstream from CREB/CBP/p300 and concerns the
relatively higher levels of cAMP generated in response to PGE2.
Figure 7. Knockdown of CREB with siRNA attenuates PGE2-
induced IL-6 protein expression in orbital fibroblasts. A: siRNA
specific to CREB (CREB si) or scrambled siRNA (Control si) was
transfected into 80% confluent cultures. Representative Western blot
analysis demonstrates the impact of the knockdown of CREB protein. B:
Media were subjected to IL-6 ELISA. Data are expressed as the mean 6
SD of three independent determinations These results were represen-
tative of those in two other orbital fibroblast strains.
doi:10.1371/journal.pone.0015296.g007
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that are more brisk in orbital cultures and might be explained by a
greater capacity for these fibroblasts to generate cAMP.
IL-6 has been insinuated in the pathogenesis of several
autoimmune diseases previously [7]. For instance, in synovial
fibroblasts derived from patients with rheumatoid arthritis, IL-6
signaling can cross-talk with that of IL-1 [45]. IL-1 suppresses IL-
6-dependent Janus kinase-STAT activity and can block the
induction by IL-6 of tissue inhibitor of metalloproteinase 1. With
regard to Graves’ disease, elevated IL-6 levels have been described
in TAO and hyperthyroidism [46]. The relatively high levels of IL-
6 provoked by PGE2 in orbital fibroblasts may, at least in part,
underlie the susceptibility of the orbit to inflammation in TAO.
The cytokine could enhance lymphocyte differentiation and
promote T cell trafficking to orbital tissues, an action promoted
through MAPK, PI3K, and the Jak/STAT pathways [47]. IL-6
promotes the synthesis of antibodies and is necessary for the
development of normal plasma cells [9]. Thus localized produc-
tion of auto-antibodies could result from the high levels of IL-6
within the orbit, potentially driving their targeting of orbital
antigens in TAO. It enhances monocyte differentiation into
macrophages at the expense of dendritic cell development [48].
IL-4 synthesis is upregulated by IL-6 at the transcriptional level
through a mechanism involving the activation of NFAT. On the
other hand, IL-6 abrogates the signaling activities of interferon-c
by up-regulating suppressor of cytokine signaling-1. STAT3
activation is required for the suppression by IL-6 of LPS-
dependent cell maturation. IL-6 also induces through STAT3
the Ifi202 gene and p202 protein in mouse splenocytes [49]. These
Figure 9. PGE2 enhances DNA binding of pCREB preferentially
in orbital fibroblasts. Eighty percent confluent cultures were serum
starved for 20 h and then treated with PGE2 (1 mM) for 16 h. Nuclear
extracts (5 mg) were subjected to the TransAM ELISA for detecting
pCREB/DNA complexes as determined at 450 nm. Data are expressed as
the mean 6 SD of triplicate independent determinations from a single
orbital and dermal fibroblast strain. They were representative of results
from 3 strains of each which demonstrated 2.1 fold greater pCREB
binding in orbital versus dermal strains.
doi:10.1371/journal.pone.0015296.g009
Figure 8. Divergent CBP/pCREB complex formation and its
importance to PGE2-dependent IL-6 expression in orbital
fibroblasts. A: Pull-down studies demonstrating CBP/pCREB protein-
protein interactions provoked by PGE2. Representative Western blot
demonstrates pCREB protein (arrow) in nuclear extracts from one
dermal and one orbital fibroblasts (input), or following immunoprecip-
itation with either anti-CBP antibody (IP-CBP) or a control antibody
(control). B: Western blot demonstrating CBP protein (arrow) in nuclear
extract (input) or following immunoprecipitation with anti-pCREB
antibody (IP-pCREB) or a control antibody (control). C: CBP knocked
down by siRNA results in diminished nuclear pCREB recruitment. pCREB
protein (arrow) in orbital fibroblast nuclear extracts (input) or following
immunoprecipitation with anti-CBP antibody (IP-CBP) in fibroblasts
transfected with CBP siRNA for 72 hr. and treated with nothing or PGE2
for 20 min. Note the absence of detectable pCREB in the immunopre-
cipitate. D: CBP knockdown reduced PGE2-induced IL-6 protein.
Cultures were transfected with either CBP siRNA or control siRNA and
treated with nothing or PGE2 (1 mM) for 16 h. Media were collected and
subjected to ELISA for IL-6. Data are expressed as the mean 6 SD of
three independent determinations. These results were confirmed in two
other orbital fibroblast strains where IL-6 production was reduced 1.2
fold by CBP siRNA.
doi:10.1371/journal.pone.0015296.g008
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TAO because Ifi202 represents a candidate susceptibility gene for
other autoimmune diseases such as lupus erythematosus. High-
level IL-6 expression in orbital fibroblasts suggests that it might
influence inflammatory responses relevant to autoimmune disease
affecting the tissues surrounding the eye. Thus, PGE2-dependent
IL-6 production in TAO might prove an important therapeutic
target.
Materials and Methods
Synthetic oligonucleotides were produced by Retrogen (Carls-
bad, CA). PGE2, 8-bromo-Sp-cAMP, LY 294002, JNK inhibitor
II, H89, and the cAMP immunoassay kit were obtained from
Calbiochem/EMD Biosciences (Gibbstown, NJ). Butaprost,
AH6809, and GW627368X came from Cayman Chemical (Ann
Arbor, MI). Anti-phospho CREB Abs were from Millipore
(Temecula, CA), and those against CREB and EP2 came from
Cell Signaling (Boston, MA) and Abcam (Cambridge, MA),
respectively. CBP siRNA was from Santa Cruz (Santa Cruz, CA)
and CREB siRNA was from Dharmacon (Lafayette, CO). An
ELISA kit for human IL-6 was from R & D Systems (Minneapolis,
MN).
Cell culture
Orbital fibroblast cultures were initiated as previously described
[27] from tissue explants obtained during decompression surgery
for severe TAO or from normal orbital tissues. Dermal fibroblasts
were obtained from normal appearing skin or were purchased
from the American Type Tissue Collection. These activities have
been approved by the Institutional Review Board of the University
of Michigan Medical Center. Fibroblasts were grown at 37uC with
95% air, 5% CO2 in poly-L-lysine-coated culture flasks and
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 2 mM glutamine, sodium pyruvate (110 mg/ml), penicillin
(100 units/ml), streptomycin (100 units/ml), 4.5% glucose and
10% fetal bovine serum (FBS). Cultures were utilized between the
fifth and seventh passage from culture initiation. Medium was
changed every three to four days.
cAMP and PGE2 assays
cAMP levels were determined in triplicate from the cell lysates
with a cAMP direct immunoassay kit (Calbiochem , San Diego,
CA) following the manufacturer’s protocol,. The sensitivity of the
assay was 0.39 pmol/ml. Cells stimulated with adenosine 39,59-
cyclic AMP, 8-Bromo-, and Sp-Isomer (Sp-cAMP), a membrane-
permeable analogue served as a positive control. For PGE2
measurements, medium was decanted and the monolayers covered
with phosphate-buffered saline in the presence of IL-1b for the
final 30 min of the incubation. PBS was collected, clarified by
centrifugation, and subjected to PGE2 EIA kit (Cayman, Ann
Arbor, MI).
Quantification of IL-6 mRNA
Total cellular RNA was isolated from cells using the RNeasy
lipid tissue mini kit (Qiagen, Valencia, CA) following manufac-
turer’s protocol. 2 units of Dnase I was treated per ,10 mgo f
RNA in a 25-100 mL reaction. cDNAs were generated by reverse
transcription of RNA using oligo(dT) and SuperScript III reverse
transcriptase (Invitrogen Inc., Carlsbad, CA). Real-time RT-PCR
was performed using cDNA preparations as templates and iQ
SYBR Green Supermix (Bio-Rad, Hercules, CA) containing real-
time PCR buffer, (iTaq DNA polymerase, dNTPs, SYBRGreen I,
fluorescein). Primers used amplified a 645 bp DNA fragment
were: forward, 5’-CAGGAGCCCAGTATAACT-3’; reverse, 5’-
GAATGCCCATGCTACATTT-3’ of the human IL-6 gene
sequence (GenBank no. NG_011640). Quantitative RT-PCR
was performed in triplicate with glyceraldehyde-3-phosphate
dehydrogenase serving as the internal control on the CFX96
Real-Time PCR system (Bio-Rad). Amplification conditions
consisted of initial 12-min activation at 95uC followed by 40
cycles of denaturation at 95uC for 30 s, annealing at 58uC for 30 s
and extension at 72uC for 30 s. Relative quantification of the PCR
amplification products was performed using the comparative
critical threshold (CT) method. The Ct value from GAPDH served
as an internal control for normalization.
Transient transfections and reporter activity assays
An 1171 bp fragment, spanning –1168 to +3 nt of the human
IL-6 gene promoter was described previously [25] (GenBank
no. NG_011640) and cloned into pGL2-basic (Promega Inc.
Madison, WI). Transient transfection of this and control constructs
into fibroblasts was achieved using Effectene reagent (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. Briefly,
2 mg of IL-6-luciferase DNA construct was transfected. Luciferase
activity was measured after 48 h by the dual assay system
(Promega Inc., Madison, WI). To assess transfection efficiency,
0.25 mg of pRL-TK plasmid DNA thymidine kinase promoter-
driven Renilla luciferase (Promega, Madison, WI) was co-
transfected with the constructs. Following cell lysis, luciferase
reporter activity was assessed in 20 ml of cell extract which was
mixed with 100 ml of the luciferase assay reagent, and firefly
luciferase activity measured as light output (10 s) in a luminometer
(Berthold Detection Systems, Huntsville, Al). The IL-6 promoter-
driven luciferase enzyme activity was expressed as a ratio to the
corresponding pRL-TK activity per unit of cellular protein.
To knock-down CREB, siRNA targeting human CREB and a
control scrambled siRNA (-ve siRNA) obtained from Dharmacon
(Lafayette, CO) at a concentration of 100 nM using RNAi as the
transfection reagent (Qiagen, Valencia, CA). Following incuba-
tions, cell lysates (15 mg protein) were subjected to Western blot
analysis. Transfection efficiency was monitored by Western blot
analysis.
Western blot analysis
Cellular proteins were solubilized in ice-cold harvest buffer
containing 0.5% Nonidet P-40, 50 mM Tris-HCl (pH 8.0), and
10 mM PMSF following the treatments indicated. Cell lysates were
taken up in Laemmli buffer and subjected to SDS-PAGE, and
separated proteins were transferred to Immobilon membrane
(Millipore). These were incubated with primary mAbs overnight at
4uC, washed and re-incubated with secondary peroxidase-labeled
Abs. The ECL (Amersham Biosciences) chemiluminescence
system was used to generate signals. Densitometric analysis of
digitized images was performed with Image J software (NIH,
Bethesda, Maryland) and band intensity normalized to that of the
corresponding b-actin band.
Quantification of IL-6 production
Confluent fibroblast monolayers in 24-well plates were shifted to
medium without or with PGE2 (unless stated otherwise, at a
concentration of 1 mM) or IL-1b (10 ng/ml) alone or in
combination with other test compounds. In some studies, cells
were serum-starved for 20 hrs and were then treated with H89
(10 mM), SB203580 (10 mM), PD98059 (10 mM), or Sp-cAMP
(1 mM) for 16 hrs. Following incubations, aliquots of medium
were collected and subjected to a specific ELISA for IL-6. Samples
were assayed in triplicate using a standard curve.
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Techniques used in these studies have been published previously
[28]. Briefly, 1610
6 cells were placed in 12675-mm polypropyl-
ene tubes and fluorochrome-conjugated mAbs were added (1 mg/
10
6 cells). These were then incubated in the dark for 20 min at
room temperature. Cells were washed twice with staining buffer,
re-suspended in Cytofix (BD Biosciences), and kept in the dark at
4uC. Within 24 h, analysis was performed on a FACSCalibur flow
cytometer (BD Biosciences). Mean fluorescent intensity (MFI) was
calculated as a ratio of mean fluorescence sample/isotype
fluorescence. To quantify binding sites represented by fluorescence
signals, 50 ml of Quantum Simply Cellular Microbeads (Sigma-
Aldrich) were incubated with 10 ml of anti-EP2 or isotype Ab for
30 min at room temperature. The bead standards consisted of four
populations of microbeads coated with anti-rabbit Ab. Each binds
a different number of mouse IgG mAb molecules (4,063, 14,354,
54,401, and 203,303 molecule-binding capacity). After Ab
addition, beads were washed three times with staining buffer.
Flow cytometric analysis was performed using the same settings as
for cell analysis. A histogram of green fluorescence (FL1) was
produced for the beads and the mean fluorescence channel
number for each peak was taken. A best-fit curve was drawn to
relate linear channel number to logarithmic binding capacity
(molecules) from which values for the EP2 and isotype controls
could be read. These were corrected for auto-fluorescence and
nonspecific binding (QuickCal; QSC calibration software). To
calibrate the fluorescence scale of the flow cytometer, we
determined the Ab-binding capacity (ABC) which represents the
number of Ab molecules bound on each cell or microbead.
Co-immunoprecipitation of nuclear proteins
Nuclear proteins were isolated using the NE-PER extraction kit
(Pierce Biotechnology, Rockford, IL). 100 mg of nuclear protein
was pre-cleared with 40 ml of 50% Protein A-agarose slurry (1:1
dilution) (Pierce) in lysis buffer containing 25 mM Tris (pH 8.0),
100 mM NaCl, 10% glycerol, Nonidet P-40, 1.5 mM MgCl2,
1 mM DTT, 1 mM PMSF, 20 mg/ml leupeptin, and 1 mg/ml
pepstatin A. All procedures were carried out on ice unless stated
otherwise. Samples were centrifuged and 10 ml of anti-CBP
antibody was incubated overnight with gentle agitation. Fifty ml
of the protein A-agarose slurry (1:1 dilution) was added and
incubated for 2 h. Protein A-agarose beads were washed in lysis
buffer and then boiled in SDS sample buffer with 100 mM DTT.
Proteins were separated on 4–15% SDS/PAGE gels and
processed for Western blotting. Membranes were probed with
1:1000 dilution of the appropriate antibodies.
Nuclear pCREB binding to DNA
Nuclear proteins from dermal and Graves’ orbital fibroblasts
were isolated using the NE-PER extraction kit (Pierce Biotech-
nology, Rockford, IL). 10 mg of nuclear extracts were used in
TransAM pCREB ELISA kit to assess the DNA-bindability of
pCREB that are present in the nuclear extracts using protein
binding CRE consensus DNA sequence and antibody targeted at
pCREB. Specificity of the DNA-bindability was validated by using
mutant DNA sequence. The TransAM
TM transcription assay kit
(Active Motif, Carlsbad,CA) was used following the manufactur-
er’s protocol.
Data Analysis
All data are presented as mean 6 S.D. Differences between two
groups were determined by the Student’s t test and significance
was achieved at p,0.05.
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